Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
- PMID: 17015809
- DOI: 10.1001/archpsyc.63.10.1074
Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Comment in
-
CUtLASS confirms CATIE.Arch Gen Psychiatry. 2007 Aug;64(8):978; author reply 979-80. doi: 10.1001/archpsyc.64.8.978-a. Arch Gen Psychiatry. 2007. PMID: 17679644 No abstract available.
Comment on
-
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).Arch Gen Psychiatry. 2006 Oct;63(10):1079-87. doi: 10.1001/archpsyc.63.10.1079. Arch Gen Psychiatry. 2006. PMID: 17015810 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical